Tools
Oseltamivir
Indications
Oseltamivir is appropriate for treating acute, uncomplicated influenza A or B illness in adults and pediatric patients, including neonates older than 2 weeks.[1] Neonates younger than 2 weeks may also receive oseltamivir for the treatment of influenza, but safety and efficacy in this population have not been established.[2]
FDA-Approved Indications
Oseltamivir has received approval from the FDA for treating and preventing both influenza A and B infections. They are indicated for managing acute, uncomplicated cases in individuals 2 weeks and older, provided symptoms have emerged within 48 hours. Additionally, oseltamivir is considered suitable for prophylactic use in patients 1 year and older.
The American Academy of Pediatrics guidelines recommend using oseltamivir to treat influenza in preterm infants, but it is not recommended for chemoprophylaxis in preterm infants. Consultation with a pediatric infectious disease physician is recommended in preterm infants younger than 28 weeks.[3] Empiric treatment with oseltamivir can shorten the duration of illness and is recommended for healthy individuals with symptoms suggestive of influenza, even before confirmation testing if treatment is initiated within 48 hours of symptoms. Multiple national advisory bodies have endorsed using oseltamivir as soon as possible (ideally less than 48 hours after symptom onset) for patients hospitalized with influenza or significant comorbidities, placing them at high risk for complications.[4]
There is evidence that oseltamivir can have efficacy in hospitalized patients up to 4 to 5 days after symptoms onset. Hence, recommendations endorse ordering oseltamivir for hospitalized patients with severe or progressive influenza or those at high risk of developing complications, regardless of symptom onset.[5] Individuals at increased risk for complications include children younger than 2, nursing home residents, adults who are obese or older than 65, pregnant women, and patients with pulmonary, liver, renal, or cardiovascular disease, malignancy, neurodevelopmental disorders, metabolic disorders, epilepsy, muscular dystrophy, and immunosuppression.
Off-Label Uses
Recommendations endorsing oseltamivir as the drug of choice for treatment and prophylaxis of illness caused by avian influenza strains, including the highly pathogenic avian influenza A (H5N1), come from the Centers for Disease Control and Prevention (CDC) and World Health Organization (WHO).
Mechanism of Action
Register For Free And Read The Full Article
Search engine and full access to all medical articles- 10 free questions in your specialty
- Free CME/CE Activities
- Free daily question in your email
- Save favorite articles to your dashboard
- Emails offering discounts
Learn more about a Subscription to StatPearls Point-of-Care
Mechanism of Action
Oseltamivir is an antiviral neuraminidase inhibitor with potent and selective competitive inhibition of the influenza virus neuraminidase, an enzyme necessary for viral replication. Oseltamivir phosphate is an inactive prodrug that exerts pharmacologic activity when hydrolyzed in vivo to the active form, oseltamivir carboxylate. This activated form interferes with the release of progeny influenza virus from infected host cells and halts the spread of infection to new host cells. Oseltamivir reduces the duration of shedding and the viral titer and can shorten the length of symptoms by 0.5 to 3 days.[6]
Mechanism of Resistance: The mechanism of resistance of influenza viruses involves antigenic drift and shift in their surface glycoproteins. Antigenic drift is the process in which minor modifications occur in key viral epitopes through point mutations; antigenic shift results in a complete exchange of hemagglutinin (HA) or neuraminidase (NA) genes. Antigenic shift emerges mainly in influenza A viruses due to their vast animal reservoirs. Antigenic shift is a process frequently associated with the outbreak of pandemics.[7]
Pharmacokinetics
Absorption: Oseltamivir is an orally administrated prodrug. The oral bioavailability of oseltamivir is approximately 80%. Oral intake does not seem to impact the pharmacokinetics of oseltamivir significantly.
Distribution: The volume of distribution is approximately 23 to 26 liters. Oseltamivir is moderately bound to plasma proteins (42%), while oseltamivir carboxylate has poor plasma protein binding.
Metabolism: Hepatic carboxylesterases extensively hydrolyze oseltamivir to the active drug oseltamivir carboxylate (OC). The active metabolite, oseltamivir, is a major circulating component (95%) in plasma, and the prodrug oseltamivir accounts for only 5% of the circulating component.
Elimination: Osaletmevir carboxylate is eliminated (>99%) through renal excretion by glomerular filtration and active tubular secretion. The half-life of oseltamivir carboxylate is 6 to 10 hours, while the half-life of oseltamivir is approximately 3 hours.[8]
Administration
Available Dosage Forms
Oseltamivir phosphate is administered orally, with or without meals, and is available in capsule form of 3 different dosages (30, 45, and 75 mg) and an oral powder for reconstitution to suspension for pediatric patients. Therapy should be initiated as early as possible, and maximum benefit is derived when started within 48 hours of the onset of illness. However, treatment must be initiated before the 48-hour window for severe illness or patients at risk of complications.
Adult Dosing
Seasonal Influenza A and B Treatment (5-day oral course) [5]
- Adults: 75 mg BID
- Infants 0 to 8 months: 3 mg/kg/dose BID
- Infants 9 to 11 months: 3.5 mg/kg/dose BID
- Children 1 to 12 yrs old:
- <15 kg: 30 mg BID
- 15 kg to 23 kg: 45 mg BID
- 23 kg to 40 kg: 60 mg BID
- >40 kg: 75 mg PO BID
Patients with severe infections admitted to an intensive care unit, or immunosuppressed may require oseltamivir treatment for a prolonged indeterminate duration (more than 5 days).
Treatment Dosing Adjustments for Creatinine Clearance
- CrCl 30 to 60 mL/min: 30 mg BID
- CrCl less than 30 mL/min: 30 mg daily
- Patients on hemodialysis: 30 mg after dialysis x 5 days (assumes 3 HD sessions)
Seasonal Influenza A and B Prophylaxis (7 to 10-day oral course)
- Adults: 75 mg daily [9]
- Infants 0 to 8 months: 3 mg/kg/dose daily (not indicated for under 3 months unless clinically critical)
- Infants 9 to 11 months: 3 mg/kg/dose daily
- Children 1 to 12 yrs old:
- <15 kg: 30 mg daily
- 15 kg to 23 kg: 45 mg daily
- 23 kg to 40 kg: 60 mg daily
- >40 kg: 75 mg daily
Prophylaxis Dosing Adjustments for Creatinine Clearance
- CrCl 30 to 60 mL/min: 30 mg daily
- CrCl less than 30 mL/min: 30 mg every other day
- End-stage renal disease: use is not recommended
While recommendations for oseltamivir include the treatment of avian influenza infections, the optimum dosage and duration of therapy are unknown for these infections.[10]
Specific Patient Populations
Hepatic impairment: According to the manufacturer's labeling information, no dosage adjustment is recommended in case of mild to moderate liver disease. In severe hepatic impairment (Child-Pugh class C), oseltamivir exposure (AUC) is elevated by a factor of 6. Use in severe hepatic impairment is not recommended.[11]
Renal impairment: The first dose should be 75 mg for patients with normal body mass. Subsequent doses should be decreased according to the degree of renal impairment. In patients on hemodialysis, reduce the oseltamivir dosage by 30 mg and an additional 30 mg after each hemodialysis session, ensuring the treatment duration does not exceed 5 days.[12]
Pregnancy considerations: Complications of influenza during pregnancy include late pregnancy loss and a decrease in mean birth weight.[13] Since pregnant and postpartum women are at increased risk of severe seasonal and pandemic influenza infection complications, the CDC recommends treatment and prevention with oseltamivir or zanamivir according to viral strain. Complications of influenza during pregnancy include late pregnancy loss and a decrease in mean birth weight.[14]
Breastfeeding considerations: Limited clinical information suggests that oseltamivir and its active metabolites are excreted into breast milk in trace amounts. Oseltamivir is a former FDA pregnancy class C. A maternal dose of 150 mg of oseltamivir daily produces low levels in milk and is not anticipated to cause adverse drug reactions in breastfed infants.[15]
Pediatric patients: For pediatric patients, administer oral suspension (6 mg/mL) based on weight. Ensure accurate dosing for infants. Use oral suspension if swallowing capsules is difficult. Postexposure prophylaxis lasts 10 days, while seasonal prevention is up to 6 weeks (or 12 weeks in immunocompromised cases). A recent study indicates that administering oseltamivir early in hospitalized children led to reduced hospitalization duration and the likelihood of 7-day readmission, ECMO use, and mortality. These results affirm the current guidelines advocating oseltamivir utilization in hospitalized children with influenza.[16]
Older patients: No dose adjustments are needed for older adults in treatment and prevention with oseltamivir, considering drug exposure and tolerability.
Adverse Effects
Oseltamivir is generally well-tolerated.[17] The most common side effects include nausea (up to 10%), vomiting (2% to 15%), abdominal pain, diarrhea, headache, insomnia, and vertigo. Vomiting is the most frequently reported side effect in children (16% of children aged 1 to 12).[18]
Other adverse effects occurring less than 1% of the time include conjunctivitis, epistaxis, allergy, arrhythmia, GI bleeding, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, confusion, seizures, and neuropsychiatric events.[6][19][20]
Cutaneous adverse drug reactions like erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis have also been reported.[21][22][23]
Serum aminotransferase elevations have been reported in 2% of clinical trials, but enzyme elevation in patients was transient and asymptomatic. The mechanism of hepatotoxicity is thought to be immunoallergic. Rare cases of liver injury and jaundice have been reported, but influenza infection can also lead to serum enzyme elevations and jaundice. Consequently, the likelihood score is D (possible rare cause of clinically apparent liver injury).[24]
Drug-Drug Interactions
Influenza antiviral medications may decrease the efficacy of LAIV4 (live attenuated influenza vaccine) if administered within 48 hours to 14 days after LAIV4.[25] Oseltamivir is an ester prodrug, and oseltamivir carboxylate contributes to the antiviral activity. Hydrolytic activation is mediated by human carboxylesterase (HCE) 1. In the presence of clopidogrel, the hydrolysis of oseltamivir is inhibited, leading to reduced antiviral efficacy.[26][27]
Contraindications
Known allergies or hypersensitivities to the drug or excipients are a contraindication to using oseltamivir. Cases of anaphylaxis have been reported.[28]
Warning and Precautions
- Commercially available oral suspension of oseltamivir contains sorbitol and saccharin sodium and should be used cautiously in patients with hereditary fructose intolerance.[29]
- Since the suspension contains sodium benzoate, watch for gasping syndrome in neonates.[30]
- Oseltamivir should not be used in patients with influenza illnesses due to strains confirmed as resistant to oseltamivir. In addition, it should not be used for diseases caused by organisms other than influenza viruses.[7]
Monitoring
Repeat RT-PCR or viral culture can determine the viral load in critically ill patients. Neuropsychiatric events, including self-injury, confusion, and delirium, should be monitored, especially in children; reports of these events in children primarily occur in Japan and have also had correlations with fatalities.[31] The influenza risk assessment tool is a systematic approach for evaluating and monitoring threats by influenza viruses.[32]
Toxicity
Oseltamivir is generally very well tolerated and has few drug interactions. Multiple animal toxicity studies, pre-marketing, and post-marketing of oseltamivir have indicated respiratory suppression resulting from central nervous system suppression, hypothermia, hypoactivity, and sudden death. This adverse event correlates with sudden-onset-type neuropsychiatric reactions in human patients (especially children from Japan), but no definitive link has been established.[33] The oseltamivir-induced liver injury requires discontinuation of the drug and avoidance of reexposure. Most patients recover after discontinuation of oseltamivir without specific interventions.[24]
Enhancing Healthcare Team Outcomes
Oseltamivir is used worldwide for treating and preventing influenza illness, both confirmed and suspected cases.[6] Consequently, clinicians should know the correct indications and uses of oseltamivir as guided by existing scientific evidence. The IDSA (Infectious Diseases Society of America) guidelines recommend oseltamivir as a first-line drug therapy for influenza.[34] The IDSA suggests that clinicians consider extended treatment in patients with immunocompromised conditions or severe lower respiratory tract involvement (acute respiratory distress syndrome or pneumonia).
If influenza is suspected during the viral season in any patient with chronic conditions or severe disease requiring hospitalization, the treating clinician must initiate oseltamivir treatment immediately, regardless of the duration of symptoms.[4] The clinician must ensure proper specimens are promptly sent to the laboratory for testing. Pathologists and clinical microbiologists are responsible for rapid testing and confirmatory results, including susceptibility testing, to ensure the optimal duration of therapy. If an immunocompromised condition is suspected, the treating clinician should consult an infectious disease specialist regarding the use of oseltamivir in influenza illness in an immunocompromised patient.[35]
In pediatric and older patients and neurodevelopmentally challenged patients, the treating clinician must partner with the nursing staff and family members to prepare the proper oseltamivir that the patient will tolerate without side effects. In addition, a pharmacist must perform medication reconciliation and dispense the appropriate dosage form of oseltamivir. In an overdose, a medical toxicologist should be consulted. Intensivist and pulmonologist consultation is vital in case of respiratory failure to deliver optimal ventilatory support in critically ill patients.[36] Intentional overdose requires referral to a psychiatrist. The responsibility of the entire healthcare team, including clinicians (MDs, DOs, NPs, PAs), nurses, specialists, and pharmacists, is to adopt an interprofessional approach to maximize efficacy, minimize adverse events, and ultimately enhance patient outcomes regarding oseltamivir pharmacotherapy.
References
Cooper NJ, Sutton AJ, Abrams KR, Wailoo A, Turner D, Nicholson KG. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials. BMJ (Clinical research ed.). 2003 Jun 7:326(7401):1235 [PubMed PMID: 12791735]
Level 1 (high-level) evidenceCOMMITTEE ON INFECTIOUS DISEASES. Recommendations for Prevention and Control of Influenza in Children, 2017 - 2018. Pediatrics. 2017 Oct:140(4):. pii: e20172550. doi: 10.1542/peds.2017-2550. Epub 2017 Sep 4 [PubMed PMID: 28870977]
COMMITTEE ON INFECTIOUS DISEASES. Recommendations for Prevention and Control of Influenza in Children, 2021-2022. Pediatrics. 2021 Oct:148(4):. pii: e2021053745. doi: 10.1542/peds.2021-053745. Epub 2021 Sep 7 [PubMed PMID: 34493538]
Fiore AE, Fry A, Shay D, Gubareva L, Bresee JS, Uyeki TM, Centers for Disease Control and Prevention (CDC). Antiviral agents for the treatment and chemoprophylaxis of influenza --- recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports. 2011 Jan 21:60(1):1-24 [PubMed PMID: 21248682]
Harper SA, Bradley JS, Englund JA, File TM, Gravenstein S, Hayden FG, McGeer AJ, Neuzil KM, Pavia AT, Tapper ML, Uyeki TM, Zimmerman RK, Expert Panel of the Infectious Diseases Society of America. Seasonal influenza in adults and children--diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2009 Apr 15:48(8):1003-32. doi: 10.1086/598513. Epub [PubMed PMID: 19281331]
Level 1 (high-level) evidenceTreanor JJ, Hayden FG, Vrooman PS, Barbarash R, Bettis R, Riff D, Singh S, Kinnersley N, Ward P, Mills RG. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA. 2000 Feb 23:283(8):1016-24 [PubMed PMID: 10697061]
Level 1 (high-level) evidenceKim H, Webster RG, Webby RJ. Influenza Virus: Dealing with a Drifting and Shifting Pathogen. Viral immunology. 2018 Mar:31(2):174-183. doi: 10.1089/vim.2017.0141. Epub 2018 Jan 26 [PubMed PMID: 29373086]
Pillai VC, Han K, Beigi RH, Hankins GD, Clark S, Hebert MF, Easterling TR, Zajicek A, Ren Z, Caritis SN, Venkataramanan R. Population pharmacokinetics of oseltamivir in non-pregnant and pregnant women. British journal of clinical pharmacology. 2015 Nov:80(5):1042-50. doi: 10.1111/bcp.12691. Epub 2015 Aug 18 [PubMed PMID: 26040405]
Welliver R, Monto AS, Carewicz O, Schatteman E, Hassman M, Hedrick J, Jackson HC, Huson L, Ward P, Oxford JS, Oseltamivir Post Exposure Prophylaxis Investigator Group. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA. 2001 Feb 14:285(6):748-54 [PubMed PMID: 11176912]
Level 1 (high-level) evidenceBeigel JH, Farrar J, Han AM, Hayden FG, Hyer R, de Jong MD, Lochindarat S, Nguyen TK, Nguyen TH, Tran TH, Nicoll A, Touch S, Yuen KY, Writing Committee of the World Health Organization (WHO) Consultation on Human Influenza A/H5. Avian influenza A (H5N1) infection in humans. The New England journal of medicine. 2005 Sep 29:353(13):1374-85 [PubMed PMID: 16192482]
Level 3 (low-level) evidenceChen Y, Ke M, Xu J, Lin C. Simulation of the Pharmacokinetics of Oseltamivir and Its Active Metabolite in Normal Populations and Patients with Hepatic Cirrhosis Using Physiologically Based Pharmacokinetic Modeling. AAPS PharmSciTech. 2020 Mar 3:21(3):98. doi: 10.1208/s12249-020-1638-y. Epub 2020 Mar 3 [PubMed PMID: 32128656]
Kamal MA, Lien KY, Robson R, Subramoney V, Clinch B, Rayner CR, Gibiansky L. Investigating clinically adequate concentrations of oseltamivir carboxylate in end-stage renal disease patients undergoing hemodialysis using a population pharmacokinetic approach. Antimicrobial agents and chemotherapy. 2015 Nov:59(11):6774-81. doi: 10.1128/AAC.01024-15. Epub 2015 Aug 17 [PubMed PMID: 26282419]
Dawood FS, Kittikraisak W, Patel A, Rentz Hunt D, Suntarattiwong P, Wesley MG, Thompson MG, Soto G, Mundhada S, Arriola CS, Azziz-Baumgartner E, Brummer T, Cabrera S, Chang HH, Deshmukh M, Ellison D, Florian R, Gonzales O, Kurhe K, Kaoiean S, Rawangban B, Lindstrom S, Llajaruna E, Mott JA, Saha S, Prakash A, Mohanty S, Sinthuwattanawibool C, Tinoco Y. Incidence of influenza during pregnancy and association with pregnancy and perinatal outcomes in three middle-income countries: a multisite prospective longitudinal cohort study. The Lancet. Infectious diseases. 2021 Jan:21(1):97-106. doi: 10.1016/S1473-3099(20)30592-2. Epub 2020 Oct 29 [PubMed PMID: 33129424]
. ACOG Committee Opinion No. 753: Assessment and Treatment of Pregnant Women With Suspected or Confirmed Influenza: Correction. Obstetrics and gynecology. 2020 Mar:135(3):734. doi: 10.1097/AOG.0000000000003708. Epub [PubMed PMID: 32080040]
Level 3 (low-level) evidence. Oseltamivir. Drugs and Lactation Database (LactMed®). 2006:(): [PubMed PMID: 30000553]
Walsh PS, Schnadower D, Zhang Y, Ramgopal S, Shah SS, Wilson PM. Association of Early Oseltamivir With Improved Outcomes in Hospitalized Children With Influenza, 2007-2020. JAMA pediatrics. 2022 Nov 1:176(11):e223261. doi: 10.1001/jamapediatrics.2022.3261. Epub 2022 Nov 7 [PubMed PMID: 36121673]
Level 2 (mid-level) evidenceHayden FG, Atmar RL, Schilling M, Johnson C, Poretz D, Paar D, Huson L, Ward P, Mills RG. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. The New England journal of medicine. 1999 Oct 28:341(18):1336-43 [PubMed PMID: 10536125]
Level 1 (high-level) evidenceMalosh RE, Martin ET, Heikkinen T, Brooks WA, Whitley RJ, Monto AS. Efficacy and Safety of Oseltamivir in Children: Systematic Review and Individual Patient Data Meta-analysis of Randomized Controlled Trials. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2018 May 2:66(10):1492-1500. doi: 10.1093/cid/cix1040. Epub [PubMed PMID: 29186364]
Level 1 (high-level) evidencePeters PH Jr, Gravenstein S, Norwood P, De Bock V, Van Couter A, Gibbens M, von Planta TA, Ward P. Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population. Journal of the American Geriatrics Society. 2001 Aug:49(8):1025-31 [PubMed PMID: 11555062]
Level 1 (high-level) evidenceKang HR, Lee EK, Kim WJ, Shin JY. Risk of neuropsychiatric adverse events associated with the use of oseltamivir: a nationwide population-based case-crossover study. The Journal of antimicrobial chemotherapy. 2019 Feb 1:74(2):453-461. doi: 10.1093/jac/dky445. Epub [PubMed PMID: 30418537]
Level 3 (low-level) evidenceSiemieniak S, Yoo MJ. Oseltamivir induced oral-only erythema multiforme. The American journal of emergency medicine. 2022 May:55():232.e1-232.e2. doi: 10.1016/j.ajem.2022.01.058. Epub 2022 Feb 1 [PubMed PMID: 35168848]
González-Ramos J, Lamas C, Bellón T, Ruiz-Bravo E, RamIrez E, Lerma V, Lecumberri B. Oseltamivir-induced toxic epidermal necrolysis in a patient with Cushing's disease. Indian journal of dermatology, venereology and leprology. 2020 Sep-Oct:86(5):515-518. doi: 10.4103/ijdvl.IJDVL_53_18. Epub [PubMed PMID: 30688217]
Zuo W, Wen LP, Li J, Mei D, Fu Q, Zhang B. Oseltamivir induced Stevens-Johnson syndrome/toxic epidermal necrolysis-case report. Medicine. 2019 May:98(19):e15553. doi: 10.1097/MD.0000000000015553. Epub [PubMed PMID: 31083216]
Level 3 (low-level) evidence. Oseltamivir. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012:(): [PubMed PMID: 31643592]
Grohskopf LA, Sokolow LZ, Broder KR, Walter EB, Fry AM, Jernigan DB. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices-United States, 2018-19 Influenza Season. MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports. 2018 Aug 24:67(3):1-20. doi: 10.15585/mmwr.rr6703a1. Epub 2018 Aug 24 [PubMed PMID: 30141464]
Shi D, Yang J, Yang D, LeCluyse EL, Black C, You L, Akhlaghi F, Yan B. Anti-influenza prodrug oseltamivir is activated by carboxylesterase human carboxylesterase 1, and the activation is inhibited by antiplatelet agent clopidogrel. The Journal of pharmacology and experimental therapeutics. 2006 Dec:319(3):1477-84 [PubMed PMID: 16966469]
Merali Z, Ross S, Paré G. The pharmacogenetics of carboxylesterases: CES1 and CES2 genetic variants and their clinical effect. Drug metabolism and drug interactions. 2014:29(3):143-51. doi: 10.1515/dmdi-2014-0009. Epub [PubMed PMID: 24988246]
Hirschfeld G, Weber L, Renkl A, Scharffetter-Kochanek K, Weiss JM. Anaphylaxis after Oseltamivir (Tamiflu) therapy in a patient with sensitization to star anise and celery-carrot-mugwort-spice syndrome. Allergy. 2008 Feb:63(2):243-4. doi: 10.1111/j.1398-9995.2007.01572.x. Epub [PubMed PMID: 18186817]
Level 3 (low-level) evidenceSingh SK, Sarma MS. Hereditary fructose intolerance: A comprehensive review. World journal of clinical pediatrics. 2022 Jul 9:11(4):321-329. doi: 10.5409/wjcp.v11.i4.321. Epub 2022 Jul 9 [PubMed PMID: 36052111]
Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol--United States. MMWR. Morbidity and mortality weekly report. 1982 Jun 11:31(22):290-1 [PubMed PMID: 6810084]
Ueda N, Umetsu R, Abe J, Kato Y, Nakayama Y, Kato Z, Kinosada Y, Nakamura M. Analysis of Neuropsychiatric Adverse Events in Patients Treated with Oseltamivir in Spontaneous Adverse Event Reports. Biological & pharmaceutical bulletin. 2015:38(10):1638-44. doi: 10.1248/bpb.b15-00253. Epub [PubMed PMID: 26424023]
Trock SC, Burke SA, Cox NJ. Development of Framework for Assessing Influenza Virus Pandemic Risk. Emerging infectious diseases. 2015 Aug:21(8):1372-8. doi: 10.3201/eid2108.141086. Epub [PubMed PMID: 26196098]
Toovey S, Prinssen EP, Rayner CR, Thakrar BT, Dutkowski R, Koerner A, Chu T, Sirzen-Zelenskaya A, Britschgi M, Bansod S, Donner B. Post-marketing assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: an updated review. Advances in therapy. 2012 Oct:29(10):826-48. doi: 10.1007/s12325-012-0050-8. Epub 2012 Oct 2 [PubMed PMID: 23054689]
Level 3 (low-level) evidenceUyeki TM, Bernstein HH, Bradley JS, Englund JA, File TM, Fry AM, Gravenstein S, Hayden FG, Harper SA, Hirshon JM, Ison MG, Johnston BL, Knight SL, McGeer A, Riley LE, Wolfe CR, Alexander PE, Pavia AT. Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2019 Mar 5:68(6):895-902. doi: 10.1093/cid/ciy874. Epub [PubMed PMID: 30834445]
Level 1 (high-level) evidenceChik KW, Li CK, Chan PK, Shing MM, Lee V, Tam JS, Yuen PM. Oseltamivir prophylaxis during the influenza season in a paediatric cancer centre: prospective observational study. Hong Kong medical journal = Xianggang yi xue za zhi. 2004 Apr:10(2):103-6 [PubMed PMID: 15075430]
Level 2 (mid-level) evidenceO'Sullivan S, Torres A, Rodriguez A, Martin-Loeches I. Influenza management with new therapies. Current opinion in pulmonary medicine. 2020 May:26(3):215-221. doi: 10.1097/MCP.0000000000000667. Epub [PubMed PMID: 32068576]
Level 3 (low-level) evidence